GT200300108A - Derivados de benzoxazina y usos de los mismos - Google Patents

Derivados de benzoxazina y usos de los mismos

Info

Publication number
GT200300108A
GT200300108A GT200300108A GT200300108A GT200300108A GT 200300108 A GT200300108 A GT 200300108A GT 200300108 A GT200300108 A GT 200300108A GT 200300108 A GT200300108 A GT 200300108A GT 200300108 A GT200300108 A GT 200300108A
Authority
GT
Guatemala
Prior art keywords
same
benzoxazine derivatives
compounds
neurotransmitter
modulators
Prior art date
Application number
GT200300108A
Other languages
English (en)
Inventor
Jacob Berger
Robin Douglas Clark
Shu-Hai Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300108A publication Critical patent/GT200300108A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA I EN LA QUE R1,R2,R3,R4,R5,R6,R7,R8,R9,Z1,P,Y,M,N, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON MODULADORES DEL NEUROTRANSMISOR 5HT6 POR LO QUE SON DE UTILIDAD EN UNA AMPLIA VARIEDAD DE CASOS TALES COMO TRASTORNOS DEL SNC, CIERTOS TRASTORNOS GASTROINTESTINALES.
GT200300108A 2002-05-13 2003-05-09 Derivados de benzoxazina y usos de los mismos GT200300108A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37800302P 2002-05-13 2002-05-13

Publications (1)

Publication Number Publication Date
GT200300108A true GT200300108A (es) 2004-03-15

Family

ID=29420358

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300108A GT200300108A (es) 2002-05-13 2003-05-09 Derivados de benzoxazina y usos de los mismos

Country Status (37)

Country Link
US (4) US6867204B2 (es)
EP (1) EP1506179B1 (es)
JP (1) JP4307377B2 (es)
KR (1) KR100636475B1 (es)
CN (1) CN100429206C (es)
AR (1) AR039988A1 (es)
AT (1) ATE316523T1 (es)
AU (1) AU2003233231B2 (es)
BR (1) BRPI0310032B8 (es)
CA (1) CA2485136C (es)
DE (1) DE60303376T2 (es)
DK (1) DK1506179T3 (es)
EA (1) EA009982B1 (es)
EC (1) ECSP045420A (es)
EG (1) EG25683A (es)
ES (1) ES2256744T3 (es)
GT (1) GT200300108A (es)
HK (1) HK1080846A1 (es)
HR (1) HRP20041030B1 (es)
IL (1) IL164928A0 (es)
JO (1) JO2413B1 (es)
MA (1) MA27118A1 (es)
MX (1) MXPA04011254A (es)
MY (1) MY139612A (es)
NO (1) NO329380B1 (es)
NZ (1) NZ536230A (es)
PA (1) PA8573501A1 (es)
PE (1) PE20040757A1 (es)
PL (1) PL211057B1 (es)
PT (1) PT1506179E (es)
RS (1) RS51042B (es)
TN (1) TNSN04225A1 (es)
TW (1) TWI258479B (es)
UA (1) UA76877C2 (es)
UY (1) UY27803A1 (es)
WO (1) WO2003095434A1 (es)
ZA (1) ZA200408783B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424825T1 (de) * 2001-07-20 2009-03-15 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
PL211057B1 (pl) * 2002-05-13 2012-04-30 Hoffmann La Roche Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny
CA2505334A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
BRPI0416873A (pt) * 2003-12-09 2007-02-27 Hoffmann La Roche derivados de benzoxazina e usos dos mesmos
ATE388712T1 (de) * 2004-01-16 2008-03-15 Hoffmann La Roche 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h- chinazolin-2-on-derivate und die jeweiligen 1h- benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erkrankungen des zentralen nervensystems
CA2566196A1 (en) * 2004-05-05 2005-11-10 F. Hoffmann-La Roche Ag Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
AU2005291542B2 (en) * 2004-09-30 2010-11-04 F. Hoffmann-La Roche Ag Compositions and methods for treating cognitive disorders
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
WO2006037481A1 (en) * 2004-09-30 2006-04-13 F.Hoffmann-La Roche Ag Benzoxazine and quinoxaline derivatives and uses
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AR078770A1 (es) * 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
KR101293384B1 (ko) * 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US9403800B2 (en) * 2012-01-24 2016-08-02 Chemregen, Inc. Compounds for inhibition of cancer cell proliferation
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029479C (zh) * 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
NZ500252A (en) 1997-04-18 2001-07-27 Smithkline Beecham P 6-(4-Methyl-piperazin-1-yl)-1H-indole derivatives useful as 5HT1A, 5HT1B and 5HT1D receptor antagonists
CA2296033A1 (en) 1997-07-11 1999-01-21 Smithkline Beecham P.L.C. Novel compounds
DE69819173T2 (de) * 1997-07-25 2004-04-15 H. Lundbeck A/S Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
JP2003521443A (ja) * 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット ４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
EP1212320B1 (en) * 1999-08-23 2005-07-06 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
PL211057B1 (pl) * 2002-05-13 2012-04-30 Hoffmann La Roche Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny

Also Published As

Publication number Publication date
JO2413B1 (en) 2007-11-11
KR100636475B1 (ko) 2006-10-18
DE60303376D1 (de) 2006-04-13
HK1080846A1 (en) 2006-05-04
UY27803A1 (es) 2003-11-28
TNSN04225A1 (fr) 2007-03-12
PE20040757A1 (es) 2004-11-06
CA2485136C (en) 2011-12-20
AU2003233231B2 (en) 2009-02-26
HRP20041030B1 (hr) 2013-03-31
MXPA04011254A (es) 2005-01-25
JP4307377B2 (ja) 2009-08-05
TW200400188A (en) 2004-01-01
MY139612A (en) 2009-10-30
NO20044665L (no) 2004-12-03
AR039988A1 (es) 2005-03-09
EG25683A (en) 2012-05-16
EP1506179B1 (en) 2006-01-25
KR20040106538A (ko) 2004-12-17
DE60303376T2 (de) 2006-11-16
US20030232825A1 (en) 2003-12-18
NO329380B1 (no) 2010-10-04
PT1506179E (pt) 2006-06-30
CN100429206C (zh) 2008-10-29
CA2485136A1 (en) 2003-11-20
DK1506179T3 (da) 2006-06-06
ES2256744T3 (es) 2006-07-16
BR0310032A (pt) 2005-02-15
EA009982B1 (ru) 2008-04-28
ATE316523T1 (de) 2006-02-15
RS51042B (sr) 2010-10-31
US20130123251A1 (en) 2013-05-16
NZ536230A (en) 2007-05-31
PL211057B1 (pl) 2012-04-30
CN1653054A (zh) 2005-08-10
WO2003095434A1 (en) 2003-11-20
JP2005530774A (ja) 2005-10-13
BRPI0310032B8 (pt) 2021-05-25
RS97004A (en) 2006-10-27
UA76877C2 (uk) 2006-09-15
PA8573501A1 (es) 2003-12-10
US20090325950A1 (en) 2009-12-31
EP1506179A1 (en) 2005-02-16
HRP20041030A2 (en) 2005-06-30
IL164928A0 (en) 2005-12-18
BRPI0310032B1 (pt) 2019-01-08
TWI258479B (en) 2006-07-21
US8377931B2 (en) 2013-02-19
MA27118A1 (fr) 2004-12-20
ZA200408783B (en) 2005-12-28
EA200401455A1 (ru) 2005-06-30
ECSP045420A (es) 2005-01-03
US20050130962A1 (en) 2005-06-16
AU2003233231A1 (en) 2003-11-11
PL374019A1 (en) 2005-09-19
US6867204B2 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
GT200300108A (es) Derivados de benzoxazina y usos de los mismos
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
GT200600159A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
GT200500183A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200300028A (es) Derivados iii de dihidrobenzodiacepina-2-ona
GT200300269A (es) Nuevos derivados fluoroglucosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
GT200300093A (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
GT200400020A (es) Compuestos de triazol utiles en terapia
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
HN2003000094A (es) Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
GT200600164A (es) Derivados de dihidrobenzofuranos y usos de los mismos
GT200600518A (es) Derivados de pirimidina
GT200300268A (es) Nuevos derivados fluoroglucosidos heterociclicos, medicamentos que contienen estos compuestos y el uso de los mismos
CR8333A (es) Derivados biciclicos [3.1.0 ] como inhibidores del transportador de glicina
GT200300098A (es) Inhibidores de metaloproteinasa de aril-heteroariloxi-ariloxi-pirimidina-2,4,6-triona
GT200300138A (es) Moduladores del receptor de glucocorticoides
GT200400032A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
GT200600072A (es) Composiciones farmaceuticas
GT200200280A (es) Lactamas como antagonistas de taquiquininas
PA8768301A1 (es) Nuevos derivados tricíclicos, su procedimiento de preparación y las composiciones farmacéuticas que lo contienen
GT200400033A (es) Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION